EVH icon

Evolent Health

10.02 USD
+0.05
0.50%
At close Feb 14, 4:00 PM EST
After hours
10.05
+0.03
0.30%
1 day
0.50%
5 days
1.21%
1 month
-10.38%
3 months
-20.92%
6 months
-62.39%
Year to date
-12.79%
1 year
-67.51%
5 years
-12.57%
10 years
-46.87%
 

About: Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Employees: 4,700

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 11 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

75% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]

51% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 39

45% more capital invested

Capital invested by funds: $2.58B [Q2] → $3.73B (+$1.16B) [Q3]

7% more funds holding

Funds holding: 243 [Q2] → 260 (+17) [Q3]

2.33% less ownership

Funds ownership: 116.06% [Q2] → 113.73% (-2.33%) [Q3]

10% less call options, than puts

Call options by funds: $75.4M | Put options by funds: $84.2M

20% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 92

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$12
20%
upside
Avg. target
$15
50%
upside
High target
$18
80%
upside

11 analyst ratings

10 positive
91%
neutral
9%
negative
0%
JMP Securities
Constantine Davides
30% 1-year accuracy
9 / 30 met price target
20%upside
$12
Market Outperform
Reiterated
14 Feb 2025
Needham
Ryan MacDonald
56% 1-year accuracy
38 / 68 met price target
50%upside
$15
Buy
Reiterated
12 Feb 2025
JP Morgan
Anne Samuel
46% 1-year accuracy
16 / 35 met price target
30%upside
$13
Overweight
Maintained
28 Jan 2025
Oppenheimer
Jeff Jones
12% 1-year accuracy
5 / 41 met price target
80%upside
$18
Outperform
Maintained
24 Jan 2025
Canaccord Genuity
Richard Close
55% 1-year accuracy
16 / 29 met price target
60%upside
$16
Buy
Maintained
23 Jan 2025

Financial journalist opinion

Based on 4 articles about EVH published over the past 30 days

Negative
Zacks Investment Research
3 days ago
Earnings Preview: Evolent Health (EVH) Q4 Earnings Expected to Decline
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Evolent Health (EVH) Q4 Earnings Expected to Decline
Neutral
PRNewsWire
1 week ago
Evolent Health Announces Changes to Board of Directors
Richard " Rick "  Jelinek to Be Named Chair of the Board at 2025 Annual Meeting Company Continues Board Refreshment Efforts with Brendan Springstubb ' s Appointment as New Independent Director WASHINGTON , Feb. 4, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced changes to its Board of Directors as part of the Company's ongoing commitment to strong corporate governance and to collaboration with shareholders. Rick Jelinek, who joined the Evolent Board as an independent director in 2023, will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott.
Evolent Health Announces Changes to Board of Directors
Negative
Zacks Investment Research
2 weeks ago
New Strong Sell Stocks for January 30th
DEC, ERO and EVH have been added to the Zacks Rank #5 (Strong Sell) List on January 30, 2024.
New Strong Sell Stocks for January 30th
Neutral
PRNewsWire
2 weeks ago
Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025
Company to Participate in Upcoming Conferences WASHINGTON , Jan. 27, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its fourth quarter 2024 financial results on Thursday, February 20, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025
Neutral
PRNewsWire
1 month ago
Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1
Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON , Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025.
Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1
Negative
Zacks Investment Research
2 months ago
New Strong Sell Stocks for December 12th
ASH, BIDU and EVH have been added to the Zacks Rank #5 (Strong Sell) List on December 12, 2024.
New Strong Sell Stocks for December 12th
Positive
Seeking Alpha
3 months ago
Evolent Health: A Shot At Revival After Market Bruising
Evolent Health has seen a significant 50% drop due to a Q3 earnings miss and high medical costs. Despite setbacks, Evolent secured record-breaking new business deals and anticipates over 15% annual revenue growth, driven by rate increases and strategic partnerships. EVH stock appears undervalued with a P/E ratio of 16.57, suggesting a potential contrarian buy opportunity given its long-term growth prospects.
Evolent Health: A Shot At Revival After Market Bruising
Neutral
Seeking Alpha
3 months ago
Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript
Evolent Health, Inc. (NYSE:EVH ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Seth Frank - Vice President, Investor Relations Conference Call Participants Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Jeff Garro - Stephens Stephanie Davis - Barclays Ryan Daniels - William Blair Matthew Gillmor - KeyBanc Kyle Aikman - J.P. Morgan Richard Close - Canaccord Genuity Sean Dodge - RBC Capital Markets Jessica Tassan - Piper Sandler Kevin Caliendo - UBS Daniel Grosslight - Citi David Larsen - BTIG Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter Ended September 30, 2024.
Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
3 months ago
Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics
Negative
Benzinga
3 months ago
Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday.
Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Charts implemented using Lightweight Charts™